Myelodysplastic syndrome (MDS) is not leukemia, but it is closely related to it. MDS is a bone marrow cancer in which abnormal stem cells make too few healthy blood cells, and in some patients the disease evolves into acute myeloid leukemia (AML). The line between the two is drawn mainly by counting immature “blast” cells in the marrow and blood, and by looking at the genetic changes inside the abnormal cells.
This question comes up constantly in clinic, and it deserves a clear answer. Below I explain what MDS is, why it sometimes turns into leukemia, how the two are told apart, and what treatment looks like at each stage. If you want the wider context first, our overview of hematology and blood health is a good starting point.
What Is Myelodysplastic Syndrome?
Myelodysplastic syndromes (the plural is often used because there are several subtypes) are a group of clonal disorders of the blood-forming stem cells. “Clonal” means the abnormal cells all descend from one damaged stem cell that has gained a growth advantage over its healthy neighbors.
The hallmark of MDS is ineffective hematopoiesis. The marrow is often full, or even overcrowded, yet the cells it produces are misshapen (dysplastic) and many die before they leave the marrow. The result is low blood counts, called cytopenias, in the circulating blood.
MDS is mainly a disease of older adults, and it becomes more common with each decade after 60. It sits within the broad family of blood disorders that arise from the marrow itself rather than from nutrient deficiency or blood loss.
Is MDS Leukemia? How the Two Are Connected
MDS and AML sit on the same spectrum. Both start from a damaged myeloid stem cell, and both involve a failure of normal blood production. The difference is largely one of degree: in MDS the abnormal cells still mature partway, while in AML they are stuck at the blast stage and pile up rapidly.
Over time, an MDS clone can acquire additional mutations. Each new “hit” can push the cells further toward immaturity until blasts dominate the marrow. When the blast count crosses the diagnostic threshold, the disease is reclassified as AML, often called “AML with myelodysplasia-related changes” or “secondary AML.”
Not everyone with MDS progresses. Many patients with lower-risk disease live for years with stable counts and never develop leukemia, while those with higher-risk features have a much greater chance of transformation.
| Feature | Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukemia (AML) |
|---|---|---|
| Marrow blasts | Below 20% (classic threshold) | 20% or more, or fewer with certain defining genetic changes |
| Main problem | Ineffective production, low counts | Rapid accumulation of immature blasts |
| Pace | Often slow, months to years | Usually rapid, days to weeks |
| Typical age | Mostly over 60 | Any age, more common in older adults |
| Treatment intensity | Supportive care to transplant, based on risk | Usually urgent induction therapy |
What causes MDS?
Most cases are primary (de novo), meaning no clear trigger is found. Age-related accumulation of mutations in stem cells is thought to be the main driver.
A smaller group is therapy-related MDS, which follows earlier chemotherapy, especially alkylating agents and topoisomerase inhibitors, or radiation therapy. These cases tend to carry high-risk genetic changes and behave more aggressively. Long-term exposure to benzene, heavy smoking, and some inherited marrow failure syndromes also raise risk.
At the molecular level, recurrent mutations are seen in genes such as TP53, ASXL1, SRSF2, SF3B1, TET2, and RUNX1. Some, like SF3B1, are associated with a gentler course, while others, like TP53, signal a higher chance of progression to leukemia.
Symptoms, Diagnosis, and Risk Scoring
Symptoms reflect which blood counts are low. Many patients are diagnosed after a routine blood test shows an unexplained drop in counts before any symptoms appear.
- Anemia (low red cells): fatigue, breathlessness, pale skin, and reduced exercise tolerance. The most common presentation, since red blood cells carry oxygen to every tissue.
- Neutropenia (low neutrophils): repeated or slow-to-clear infections.
- Thrombocytopenia (low platelets): easy bruising, nosebleeds, bleeding gums, or tiny red skin spots called petechiae.
Diagnosis starts with a complete blood count and a blood film, then moves to a bone marrow aspirate and biopsy. The pathologist looks for dysplasia in the red cell, white cell, and platelet lines and counts the blasts. Cytogenetic testing and next-generation sequencing identify chromosome and gene changes. Doctors also rule out look-alikes such as vitamin B12 or folate deficiency, copper deficiency, alcohol effects, and certain medications, all of which can mimic MDS on a blood film.
Risk scoring: predicting the path to leukemia
Once MDS is confirmed, it is classified (using the WHO or International Consensus Classification) and then risk-scored. The most widely used tools are the Revised International Prognostic Scoring System (IPSS-R) and its molecular update, the IPSS-M.
These scores combine the marrow blast percentage, the chromosome findings, and the depth of each cytopenia; the IPSS-M adds gene mutations. Patients are then grouped from very low to very high risk. The score estimates both expected survival and the likelihood of transformation to AML, and it is the single most useful guide to treatment.
Treatment: From Supportive Care to Transplant
Treatment is risk-adapted. The goal in lower-risk MDS is to improve blood counts and quality of life; in higher-risk MDS it is to delay or prevent leukemia and extend survival.
Lower-risk MDS
- Red cell transfusions for symptomatic anemia, with iron chelation if iron overload develops.
- Erythropoiesis-stimulating agents (ESAs) to boost red cell production.
- Lenalidomide for MDS with isolated deletion 5q, which often responds well.
- Luspatercept for selected patients with anemia, particularly those with ring sideroblasts or SF3B1 mutations.
Higher-risk MDS
- Hypomethylating agents such as azacitidine and decitabine, which can improve counts and slow progression.
- Allogeneic stem cell transplantation, currently the only treatment that can cure MDS, reserved for fit patients because of its risks.
- Clinical trials of targeted agents for specific mutations.
In my practice, the treatment conversation always starts with the risk score and the patient’s own priorities. Two people with the same diagnosis may reasonably choose very different paths.
When to See a Doctor
If you have MDS, contact your hematology team promptly if you notice any of the following, as they can signal falling counts or progression:
- Fever of 38°C (100.4°F) or higher, especially if you are neutropenic.
- New or worsening bruising, bleeding, or petechiae.
- Rapidly increasing fatigue or breathlessness, or needing transfusions more often.
- Bone pain, night sweats, or unexplained weight loss.
Without a diagnosis, persistent unexplained low blood counts on a routine test deserve a hematology review rather than a wait-and-see approach. You can read more about related conditions in our guide to hematological disorders, and our leukemia guide covers AML and other leukemias in depth.
Frequently Asked Questions
Is MDS considered a type of cancer?
Yes. MDS is a clonal bone marrow cancer, even though it often behaves more slowly than leukemia. That is why it is managed by hematologists and oncologists and why some treatments overlap with cancer therapy.
Will my MDS definitely turn into leukemia?
No. Many people with lower-risk MDS never develop AML, and their main issue remains low blood counts. Your IPSS-R or IPSS-M score gives the best individual estimate of risk.
How will my doctor know if MDS is progressing?
Regular blood counts track trends, and a rising need for transfusions or the appearance of blasts in the blood can prompt a repeat bone marrow test. A marrow blast count at or above the AML threshold confirms transformation.
Can MDS be cured?
Allogeneic stem cell transplantation is the only potentially curative option. For patients who are not transplant candidates, other treatments can control the disease and improve quality of life for long periods.
Key Takeaways
- MDS is a clonal marrow disorder, not leukemia, but it can progress to acute myeloid leukemia.
- The distinction rests mainly on the marrow blast percentage and specific genetic changes.
- Risk scores such as IPSS-R and IPSS-M predict both survival and the chance of transformation.
- Treatment ranges from transfusions and growth factors to hypomethylating agents and transplant.
